GHRH analogue · defined clinical populations
What is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing factor analogue. It stimulates the pituitary growth-hormone pathway. It has been studied for excess visceral fat, the fat around internal abdominal organs, in defined patient groups.
How does Tesamorelin work?
GHRH-related signalling can increase growth hormone and IGF-1 activity. Visceral fat is different from subcutaneous fat beneath the skin, so a change in one does not mean the whole body loses fat in the same way. [1]
What does the research show?
A randomised study published in 2007 investigated tesamorelin in people with HIV-associated abdominal fat accumulation. It measured visceral-fat changes using imaging. This is a specific medical research setting, not a general cosmetic weight-loss claim. [1]
What the evidence does not establish
Findings in HIV-associated fat accumulation should not automatically be transferred to healthy people seeking a flatter abdomen. The exact formulation and monitoring requirements also matter.
Safety questions to discuss
The official EGRIFTA information discusses glucose intolerance, IGF-1 monitoring and contraindications. A qualified professional must interpret those issues for the individual. [2]
Frequently asked questions
Is visceral fat the same as fat under the skin?
No. Visceral fat surrounds internal organs; subcutaneous fat sits beneath the skin.
Does this establish tesamorelin as a general slimming product?
No. Its clinical evidence must be read in the specific population and indication studied.
Sources and further reading
- Tesamorelin in patients with HIV — randomised clinical study, 2007
- EGRIFTA SV official product information
These are selected sources, not a systematic review. Check publication dates, study methods and the exact substance tested. Artwork does not establish clinical benefit.